Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.60 |
| ▸ | MAOA | P21397 | 2/20 | 0.58 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | GRM5 | P41594 | 1/20 | 0.57 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425539 | 1.00 | MAOB (0.60) | MAOBMAOASCN9ANR4A2GRM5 | |
| SCHEMBL4425117 | 0.86 | MAOB (0.57) | MAOBMAOASCN9ANR4A2GRM5 | |
| SCHEMBL4425123 | 0.86 | MAOB (0.57) | MAOBMAOASCN9ANR4A2GRM5 | |
| SCHEMBL4553294 | 0.85 | MAOB (0.60) | MAOBMAOA | |
| SCHEMBL4429849 | 0.85 | MAOB (0.60) | MAOBMAOA | |
| SCHEMBL4429845 | 0.85 | MAOB (0.60) | MAOBMAOA | |
| SCHEMBL5035179 | 0.84 | MAOB (0.61) | MAOBMAOASCN9ANR4A2GRM5 | |
| SCHEMBL3288764 | 0.82 | MAOB (0.78) | MAOBMAOASCN9A | |
| SCHEMBL1070381 | 0.82 | MAOB (0.78) | MAOBMAOASCN9A | |
| SCHEMBL8431825 | 0.81 | MAOB (0.62) | MAOBMAOASCN9ANR4A2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761480-B1 | MAO-B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-02-18 | — | — | EP | claimed |
| US-7253318-B2 | Benzyloxy derivatives as MAOB inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | claimed |
| EP-1761480-A2 | NEW MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | claimed |
| WO-2006000324-A2 | NEW MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | WO | claimed |
| US-20050288367-A1 | Benzyloxy derivatives as MAOB inhibitors | HOFFMAN-LA ROCHE INC. | 2005-12-29 | — | — | US | claimed |
| EP-1761480-B1 | MAO-B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-02-18 | — | — | EP | disclosed |
| US-7253318-B2 | Benzyloxy derivatives as MAOB inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1761480-A2 | NEW MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006000324-A2 | NEW MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288367-A1 | Benzyloxy derivatives as MAOB inhibitors | HOFFMAN-LA ROCHE INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288367-A1 | Benzyloxy derivatives as MAOB inhibitors | MAOB, MAOA, COMT | MAOB 1/4885MAOA 2/4885SCN9A 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.